Swissray International has released more details on its plans to reorganize the company (SCAN 2/18/98). In a move designed to focus the firm on digital imaging, the New York City-based digital radiography developer has signed a letter of intent to
Swissray International has released more details on its plans to reorganize the company (SCAN 2/18/98). In a move designed to focus the firm on digital imaging, the New York City-based digital radiography developer has signed a letter of intent to sell its Swissray Empower U.S. film and x-ray accessories division to distributor E.M. Parker, based in Wilmington, MA.
Terms of the transaction are still being negotiated, with a completion date expected during the current fiscal year, according to Swissray. Swissray had acquired the Empower business in April 1997 as part of the firm's attempt to offer a wide range of products and services to customers.
In other reorganization developments, the company's board of directors has decided to restructure its senior management as part of a plan to grow Swissray beyond a developmental-stage company, said Ruedi Laupper, chairman. A search is under way for a new CEO and CFO. Laupper, who previously also held the titles of president and CEO, retains primary responsibility for day-to-day operations.
In other company news, Swissray has sold another AddOn-Multi-System, to Dutchess Radiology Associates of Poughkeepsie, NY. Financial terms of the sale were not released.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.